Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Hepatitis B vaccine (rDNA)
HBVAXPRO 5µg · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| HBVAXPRO Challenge dose | EXPERIMENTAL | HBVAXPRO 5µg |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HBVAXPRO 5µg | BIOLOGICAL | 0.5mL intramuscular injection |
| HBVaxPRO® 5 µg / 0.5 mL | BIOLOGICAL | 5 µg / 0.5 mL |
| Engerix B® 10 µg / 0.5 mL | BIOLOGICAL | 10 µg |
Inclusion Criteria: * Healthy child * Child vaccinated with 3 doses of HEXAVAC or 3 doses of INFANRIX HEXA as infant * Child vaccinated with the third dose of HEXAVAC or INFANRIX HEXA at least 10 years prior to challenge dose Exclusion Criteria: * Receipt of more than 3 doses of any Hepatitis B c...
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |
HBVAXPRO 5µg is a hepatitis B vaccine used to prevent hepatitis B virus infection. It is studied in children and is given as a challenge or booster dose to assess immune response in individuals previously vaccinated against hepatitis B. The drug is also referred to as HBVaxPRO 5 µg / 0.5 mL.
HBVAXPRO 5µg is developed and manufactured by Sanofi, which trades under the ticker SNY. Sanofi is a global pharmaceutical company that produces vaccines and other therapeutic products.
HBVAXPRO 5µg is in Phase 3 clinical development. It is an investigational product and has been evaluated in completed Phase 3 trials. The development stage reflects ongoing clinical research rather than approved marketing status.
HBVAXPRO 5µg has been studied in completed Phase 3 trials including NCT02012998, which enrolled 751 healthy children in Italy, and NCT00693186, which enrolled 410 healthy children in Italy. Both trials assessed immune responses after prior vaccination with HEXAVAC or INFANRIX HEXA.